Stockreport

KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com
PDF $49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 20251,702 patient start forms received in the US from launch [Read more]